Zoo Book Sales
Related Articles
ARLINGTON, TX (May 5, 2021) – Nanoscope Technologies LLC, a biotechnology company developing gene therapies for the treatment of retinal disease, presents several scientific presentations highlighting its groundbreaking research into optical delivery of genes for the restoration of vision and OCT-guided electrophysiology platforms for characterization of retinal degeneration and evaluation of the efficacy of cell gene therapy at the (virtual) annual meeting of ARVO 2021, May 1-7.
ARVO, the Association for Vision and Ophthalmology Research, is the world’s largest eye and vision research organization with nearly 11,000 members in over 75 countries.
Nanoscope’s flagship product is an optogenetic gene therapy, vMCO-010, which delivers light-sensitive Multiple Characteristic Opsin (MCO) into retinal cells to restore vision in patients with retinal degeneration. If successful, optogenetic therapy would be the first treatment aimed at correcting these retinal diseases.
Nanoscope is also developing an alternative method of gene delivery based on non-viral light, designed to be more targeted with less immunogenicity. Upcoming presentations below, on Thursday, May 6, will highlight Nanoscope’s Optical Coherence Tomography (OCT) guided optical gene delivery platform technology enabling robust OCD expression in degenerate retina and the OCT-guided electrophysiology platform to monitor the efficacy of cell gene therapy.
Optical coherence tomography guided laser gene delivery to degenerate retina
Author (s): Biraj Mahato, Sanghoon Kim, Houssam Al-Saad, Subrata Batabyal, Michael Carlson, Samarendra Mohanty
10:15 a.m. – 12:00 p.m. CDT Thursday, May 6
Valeria Canto Soler, Ph.D., director of the CellSight Program in Ocular Stem Cells and Regeneration at the University of Colorado, Denver School of Medicine, will highlight the OCT-guided micro-focal ERG system of Nanoscope with multiple stimulus wavelengths for characterizing eye health as part of his speech.
3:30 p.m. to 3:42 p.m. CDT Thursday, May 6
Additionally, on Saturday May 1, Nanoscope Founder, President and Scientific Director Samarendra Mohanty, Ph.D. led a presentation titled: An OCT-Guided Laser Microirradiation System for the Development of an Animal Model of Degeneration retina Author (s): Sanghoon Kim, Michael Carlson, Subrata Batabyal, Weldon Wright, Samarendra Mohanty
###
About Nanoscope Technologies LLC.
Nanoscope Technologies, LLC, founded in 2009 by Samarendra Mohanty, PhD., Has received multiple SBIR awards, National Institutes of Health (NIH) R01 grants, and patents that focus on optical stimulation, gene delivery, and imaging for monitoring neuronal activity. She separated several companies Nanoscope Therapeutics Inc, Nanoscope Instruments Inc, Nanoscope Diagnostics LLC and Opsin Biotherapeutics Inc for the commercialization of platform technologies.
Warning: AAAS and EurekAlert! are not responsible for the accuracy of any press releases posted on EurekAlert! by contributing institutions or for the use of any information via the EurekAlert system.
